Furthermore, studies have found that naïve CD4+ T cells increase in CLL patients with ibrutinib treatment (21, 79), and a large proportion of naïve T cells in CLL (greater than 10%) express T-BET or EOMES (21), indicating the differentiation is skewed to Th1 cells. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.